Effect and Underlying Immunological Mechanisms of Sublingual Immunotherapy in Allergic Rhinitis

Launched by BEIJING TONGREN HOSPITAL · Aug 26, 2018

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female outpatients aged 18 to 60 years (inclusive).
• • With history of SAR for at least two years, with/without conjunctivitis and asthma
• • Two or more nasal symptoms scores were ≥ 2 points during July - October in the last year.
• • Sensitised to artemisia annua (specific IgE level ≥ 3.5 kilounit per liter).
• • Patients who have been informed of the nature and aims of the study and have given their written consent, willing to comply with the protocol.
• • Patients who are able to understand the information given and the consent and complete the daily record card.
• Exclusion Criteria:
• • Patients whose Humulus- or Artemisiifolia-specific immunoglobulin E (IgE) levels (ImmunoCAP) same as or higher than Artemisia-specific immunoglobulin E (IgE) level.
• • Patients with oral diseases/ allergies within the run-in period.
• • Patients accepted any kind of operations within 4 weeks of the run-in period.
• • Patients applied for systemic glucocorticoids within 4 weeks in the run-in period.
• • Patients with perennial AR.
• • Patients with any nasal condition that could confound the results of the study (chronic rhinitis, chronic rhinosinusitis with/without polyps).
• • Whatever the co-sensitization leading to clinically relevant AR, conjunctivitis or asthma likely to significantly change the symptoms of the patient throughout the study.
• • Patients with comorbidity of severe asthma.